Compare MDU & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDU | OCUL |
|---|---|---|
| Founded | 1924 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.4B |
| IPO Year | N/A | 2014 |
| Metric | MDU | OCUL |
|---|---|---|
| Price | $19.61 | $14.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $22.00 | ★ $22.56 |
| AVG Volume (30 Days) | 2.4M | ★ 3.8M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $1,876,593,000.00 | $55,783,000.00 |
| Revenue This Year | $9.10 | N/A |
| Revenue Next Year | $3.08 | $14.88 |
| P/E Ratio | $23.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.04 | $5.79 |
| 52 Week High | $21.49 | $16.44 |
| Indicator | MDU | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 43.27 | 60.83 |
| Support Level | $19.22 | $11.15 |
| Resistance Level | $19.78 | $16.44 |
| Average True Range (ATR) | 0.33 | 0.77 |
| MACD | -0.15 | 0.24 |
| Stochastic Oscillator | 18.35 | 59.49 |
MDU Resources Group Inc operates in three business segments, which include the electric segment, which generates, transmits, and distributes electricity in Montana, North Dakota, South Dakota, and Wyoming; The natural gas distribution segment distributes natural gas in those states, as well as in Idaho, Minnesota, Oregon, and Washington; The pipeline segment provides natural gas transportation and underground storage services through a regulated pipeline system in the Rocky Mountain and northern Great Plains regions of the United States.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.